

## Biomarkers in atrial fibrillation

Angelika Hammerer-Lercher, Nicolas Vuilleumier

### References

1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. *Clin Epidemiol* 2014;6:213-20.
2. Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, Markl M et al. Evaluating the Atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. *Circulation* 2015; 132(4): 278–291.
3. Jalife J. Mechanisms of persistent atrial fibrillation. *CO Cardiology* 2013;29(1):20-27.
4. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analysis. *Circ Arrhythm Electrophysiol.* 2009;2:349-61.
5. Menezes AR, Lavie CJ, DiNicolantonio JJ, O’Keefe J, Morin DP, Khatib S, Milani RV. Atrial Fibrillation in the 21<sup>st</sup> Century: A Current Understanding of Risk Factors and Primary Prevention Strategies. *Mayo Clin Proc* 2013;88:394-409.
6. Amdur RL, Mukherjee M, Go A, Barrows IR, Ramezani A, Shoji J, Reilly MP et al. Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. *PLoS One* 2016;11(2):e0148189.
7. Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. *Eur Heart J.* 2019;40(16):1268-1276.
8. Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I, Vartiainen E et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium. *Circulation* 2017;136(17):1588-1597.
9. Magnussen C, Ojeda FM, Wild PS, Sørensen N, Rostock T, Hoffmann BA, Prochaska J et al. Atrial Fibrillation Manifestations Risk Factors and Sex Differences in a Population-Based Cohort (From the Gutenberg Health Study). *Am J Cardiol* 2018;122(1):76-82.
10. Proietti M, Laroche C, Nieuwlaat R, Crijns HJGM, Maggioni AP, Lane DA, Boriani G. et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. *Eur J Intern Med* 2018;55:28-34.
11. Gutierrez A, Van Wagoner DR. Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update. *J Cardiovasc Pharmacol* 2015;66(6):523-529.
12. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 2005;95(6):764-767.
13. Ravelli F. Mechano-electric feedback and atrial fibrillation. *Circulation* 2003;108:3006-10.
14. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, et al. FGF23 induces left ventricular hypertrophy. *J Clin Invest* 2011;121:4393-408.

15. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. *Circulation* 2010;121(2):200-207.
16. Svennberg E, Lindahl B, Berglund L, Eggers KM, Venge P, Zethelius B, Rosenqvist M et al. NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach. *Int J Cardiol* 2016;223:74-81.
17. Deng H, Shantsila A, Guo P, Zhan X, Fang X, Liao H, Liu Y et al. Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project. *J Arrhythm* 2018;34(6):617-625.
18. Anegawa T, Kai H, Adachi H, Hirai Y, Enomoto M, Fukami A, Otsuka M et al. High-sensitive troponin T is associated with atrial fibrillation in a general population. *Int J Cardiol* 2012;156(1):98-100.
19. Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, Loehr LR et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2015;169(1):31-38.
20. Hussein AA, Bartz TM, Gottdiener JS, Sotoodehnia N, Heckbert SR, Lloyd-Jones D, Kizer JR et al. Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. *Heart Rhythm* 2015;12(5):879-885.
21. Stoyanov KM, Giannitsis E, Biener M, Mueller-Hennessen M, Arens K, Katus HA, Vafaie M. Prognostic value of elevated high-sensitivity cardiac troponin T in patients admitted to an emergency department with atrial fibrillation. *Europace* 2018;20(4):582-588.
22. Bai Y, Guo SD, Liu Y, Ma CS, Lip GYH. Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: a systematic review, meta-analysis and meta-regression. *Biomarkers* 2018;23(6):512-517.
23. Lee Y, Park HC, Shin JH, Lim YH, Shin J, Park JK. Single and persistent elevation of C-reactive protein levels and the risk of atrial fibrillation in a general population: The Ansan-Ansung Cohort of the Korean Genome and Epidemiology Study. *Int J Cardiol* 2019;277:240-246
24. Shen H, Wang J, Min J, Xi W, Gao Y, Yin L, Yu Y et al. Activation of TGF- $\beta$ 1/ $\alpha$ -SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients. *Cell Physiol Biochem* 2018;47(2):851-863.
25. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. *Circ Heart Fail* 2013;6(1):107-117.
26. Takemoto Y, Ramirez RJ, Yokokawa M, Kaur K, Ponce-Balbuena D, Sinno MC, Willis BC et al. Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes. *JACC Basic Transl Sci* 2016;1(3):143-154.
27. Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, Yorgun H, Sahiner ML et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. *Am J Cardiol* 2015;115(5):647-651.
28. Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD et al. Galectin 3 and incident atrial fibrillation in the community. *Am Heart J* 2014;167(5):729-734.
29. Tang Z, Zeng L, Lin Y, Han Z, Gu J, Wang C, Zhang H. Circulating Galectin-3 is Associated With Left Atrial Appendage Remodelling and Thrombus Formation in Patients With Atrial Fibrillation. *Heart Lung Circ* 2018 [Epub ahead of print]
30. Shao Q, Liu H, Ng CY, Xu G, Liu E, Li G, Liu T. Circulating serum levels of growth differentiation factor-15 and neuregulin-1 in patients with paroxysmal non-valvular atrial fibrillation. *Int J Cardiol* 2014;172(2):e311-3.
31. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Circulation* 2014;130(21):1847-1858.
32. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. *Clin Chem* 2017;63(1):152-164.
33. Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW et al. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. *JAMA Cardiol*. 2018 [Epub ahead of print]
34. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. *Nat Rev Drug Discov*. 2008;7(10):827-840.
35. Seki K, Sanada S, Kudinova AY, Steinhilber ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. *Circ Heart Fail*. 2009;2(6):684-691.

36. Nortamo S, Ukkola O, Lepojärvi S, Kenttä T, Kiviniemi A, Juntila J, Huikuri H, Perkiömäki J. Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease. *Int J Cardiol.* 2017;248:173-178.
37. Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, McCabe EL et al. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. *Am Heart J.* 2014;167(1):109-115.